In January 2019, WHO  defined the growing number of vaccine critics as one of the ten greatest threats to global health, and since the unprecedented corona vaccination fiasco , the number of vaccine refusers has really multiplied. Meanwhile, resistance is emerging even within the conventional medical community. But the masterminds at WHO continue to insist on an unrealistic vaccination rate of at least 70 percent.
Now several experts and former mainstream journalists like John O’Sullivan are warning that the massive PCR testing campaign could be a WHO vaccination program in disguise. (see Principia Scientific)  O’Sullivan is referring to a new technology developed at Johns Hopkins University that is supposed to make it possible to carry out covert vaccinations through a PCR test. (See Johns Hopkins Universitiy) 
Inspired by a parasitic worm that digs its sharp teeth into the intestines of its host, Johns Hopkins researchers have developed tiny, star-shaped micro-devices that attach to the intestinal mucosa and can deliver drugs into the body.
These tiny devices, known as “Theragrippers,” are made of metal and a thin film that changes shape. They are covered with heat-sensitive kerosene wax and each no larger than a dust particle.
When the kerosene coating on the Theragripper reaches body temperature, the devices close autonomously and clamp onto the wall of the colon. Because of the sealing action, the tiny, six-pointed devices burrow into the mucosa and attach to the colon, where they are held and gradually release their drug load to the body. Eventually, the Theragripper lose their grip on the tissue and are removed from the colon through normal gastrointestinal muscle function.
The Johns Hopkins University research team published positive results from an animal study as a cover article in Science Advances on October 28, 2020 , confirming that the new technology works flawlessly:
Here we report that GI parasite-inspired active mechanochemical therapeutic grabs, or theragrippers, can survive 24 hours in the gastrointestinal tract of live animals by autonomously adhering to mucosal tissue. We also observe a remarkable six-fold increase in elimination half-life when using ripper-mediated delivery of the model analgesic ketorolac tromethamine. These results provide excellent evidence that shape-shifting and self-locking microdevices improve the effectiveness of long-term drug delivery.